WuXi Biologics (Cayman) Inc. (WUXI BIO) filed its monthly return with the Hong Kong Stock Exchange for the period ended 30 September 2026, detailing a net reduction of 29.02 million ordinary shares.

Authorised Capital • Authorised share capital remained unchanged at USD 50,000, representing 6.00 billion ordinary shares with an unchanged par value of USD 1/120,000 per share.

Issued Shares • Outstanding shares fell to 4.12 billion from 4.15 billion, a 0.70% month-on-month contraction. • Public float continues to exceed the 15% minimum requirement.

Key Movements 1. Share Buybacks and Cancellations – 39.82 million shares previously repurchased were cancelled on 18 September 2026. – The stated average repurchase price was HKD 31.93, implying a cash outlay of approximately HKD 1.27 billion (about USD 162 million).

2. Option Exercises – 10.81 million new shares were issued under Pre-IPO Share Option Schemes at exercise prices ranging from USD 0.2633 to USD 0.6000, raising USD 3.68 million.

Equity Incentive Pipeline • Up to 98.78 million additional shares may be issued under the company’s Restricted Share Award Scheme and Global Partner Program, subject to future vesting and grant conditions.

As of 30 September 2026, WUXI BIO’s total issued share capital stood at 4.12 billion ordinary shares, positioning the company with a reduced share count and maintained compliance with HKEX public-float regulations.